|1.||Sautès-Fridman, Catherine: 3 articles (12/2008 - 11/2002)|
|2.||Cassard, Lydie: 3 articles (12/2008 - 11/2002)|
|3.||Ravetch, Jeffrey V: 2 articles (05/2015 - 09/2014)|
|4.||Drake, Charles G: 2 articles (01/2014 - 07/2008)|
|5.||Fridman, Wolf H: 2 articles (12/2008 - 11/2002)|
|6.||Sastre-Garau, Xavier: 2 articles (12/2008 - 11/2002)|
|7.||Camilleri-Broët, Sophie: 2 articles (12/2008 - 12/2006)|
|8.||Barua, Animesh: 2 articles (04/2007 - 08/2005)|
|9.||Rotmensch, Jacob: 2 articles (04/2007 - 08/2005)|
|10.||Kebede, Tewabe: 2 articles (04/2007 - 08/2005)|
01/01/1984 - "Monoclonal anti-tumor antibodies offer strong promise for clinical use, initially for tumor diagnosis and, ultimately, also for therapy."
04/01/1983 - "Monoclonal anti-tumor antibodies have great promise for radioimmunodetection and localization of tumors. "
08/01/2005 - "In addition to characterization of anti-tumor antibodies as diagnostic markers, study of anti-tumor antibodies is likely to provide insights into mechanisms of tumor development. "
10/01/1983 - "Since then, various trials for tumor detection have been performed using anti-tumor antibodies. "
01/01/1981 - "The objective of this study was to investigate whether natural anti-tumor antibodies (NAb) contributed to the surveillance of small inocula of syngeneic tumors. "
09/01/1979 - "Detection of tumor antibodies in patients with gastrointestinal carcinomas by a solid-phase radioimmunoassay."
06/01/1984 - "[Immunological studies on spontaneous colon carcinoma of Wistar-Furth rats: demonstration of tumor antigens and syngeneic anti-tumor antibodies]."
07/01/1993 - "We investigated the ability of bispecific anti-T-cell receptor x anti-tumor antibodies, destined for the study of T-cell retargeting in a rat colon carcinoma model, to enhance tumor neutralization by polyclonally activated CD8+ T lymphocytes in hepatic subcapsular Winn type assays against syngeneic CC531 colon carcinoma cells. "
01/01/1983 - "A total of 208 plasma samples from 115 patients with gastrointestinal carcinomas and nine patients with other intestinal disease were examined for the presence of IgE tumor antibodies by a solid-phase radioimmunoassay. "
|3.||Neoplasm Metastasis (Metastasis)
11/01/1987 - "Recently immunoscintigraphy with radiolabeled monoclonal anti-tumor antibodies has become popular and transmission whole-body scintigraphy has been re-evaluated to make diagnosis for laterality of metastases. "
01/01/1983 - "If anti-tumor antibodies are used in this way it may be possible to detect lymph node metastasis. "
10/15/1979 - "The present study was undertaken in order to evaluate the possibility of using anti-tumor antibodies as specific carriers of chemotherapeutic drugs to tumor metastases. "
02/27/1987 - "From these results, it can be concluded that the corresponding tumor antibodies should be selected on the basis of immunohistochemical investigations of the primary tumor before performing radioimmunoscintigraphy to screen for recurrences or metastases."
01/01/2000 - "Initial trials with antiangiogenic (angioinhibitor) therapy such as anti-VEGF antibodies, anti-VEGF receptor antibodies, tumor necrosis factor, and metalloproteinase inhibitors have been reported and antitumor activity observed in a limited number of patients with advanced (inoperable or metastatic) disease."
12/01/2013 - "Plasma levels of Hsp60, Hsp70, and their specific antibodies, tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, IL-10, IL-12, and soluble TNF-α-receptor I (sTNFRI) concentrations, were determined by enzyme-linked immunosorbent assay (ELISA). "
12/15/2000 - "In stable selected CASP-2L-Pro-transfected Namalwa cells, overexpression of caspase-2L-Pro delayed apoptotic DNA fragmentation induced by death receptor agonists (anti-Fas antibodies, tumor necrosis factor-alpha) and DNA topoisomerase I- (camptothecin) and II- (etoposide) inhibitors, and prevented etoposide-induced activation of the caspase cascade. "
09/01/1999 - "Blood samples were obtained from in-dwelling lines or direct venipuncture within 12 h of admission and 24 hourly thereafter for measurements of plasma endotoxin, EndoCab immunoglobulin (Ig)G and IgM antibodies, tumor necrosis factor (TNF), p55 TNF receptor, and IL-6. "
01/01/1983 - "Studies are in progress to further define the radiological appearance of gliomas, to evaluate contrast-tagged anti-tumor antibodies as a diagnostic tool in evaluating gliomas by computerized tomography, and to evaluate metabolic parameters of actrocytomas by positron emission tomography."
06/24/1978 - "Anti-tumor antibodies have been searched for with an antibody-dependent cell-mediated cytotoxicity assay in the sera of patients with glioma. "
06/24/1978 - "[Anti-tumor antibodies in the blood of patients with gliomas]."
09/01/1981 - "The presence of natural anti-tumor antibodies (NAA) against fibrosarcoma- and glioma cells was revealed in the normal sera of 10 different strains of rats. "
09/01/1981 - "[Cytotoxic natural anti-tumor antibodies against fibrosarcoma and glioma cells in rats (author's transl)]."
|1.||Fc Receptors (Fc Receptor)
|2.||Complement System Proteins (Complement)
|5.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|6.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|7.||Immune Sera (Antisera)
|8.||Neoplasm Antigens (Tumor Antigens)
|9.||Antigen-Antibody Complex (Immune Complex)
|3.||Drug Therapy (Chemotherapy)